2026-04-17T13:44:33Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4557132026-03-21T03:22:22Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Aguado, Cristina author Teixidó, Cristina author Román, Ruth author Reyes, Roxana author Giménez-Capitán, Ana author Marin, Elba author Cabrera-Lopez, Carlos author Viñolas, Nuria author Castillo, Sergi author Muñoz, Silvia author Arcocha, Ainara author López Vilaró, Laura author Sullivan, Ivana author Aldeguer, Erika author Rodríguez, Sonia author Moya, Irene author Viteri, Santiago author Cardona Zorrilla, Andrés Felipe author Palmero, Ramon author Sainz, Cristina author Mesa-Guzmán, Miguel author Lozano, Maria D. author Aguilar-Hernández, Andrés author Martínez-Bueno, Alejandro author González-Cao, María author Gonzalvo, Elena author Leenders, William P. J. author Rosell, Rafael author Montuenga, Luis M. author Prat, Aleix author Molina Vila, Miguel Ángel author Reguart, Noemi author 2020 We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3.5% with very-high MET mRNA expression, a surrogate of MET amplification. MET alterations identified by nCounter correlated with clinical benefit from MET inhibitors. Quantitative mRNA-based techniques can improve the selection of patients for MET-targeted therapies. MET inhibitors have shown activity in non-small-cell lung cancer patients (NSCLC) with MET amplification and exon 14 skipping (METΔex14). However, patient stratification is imperfect, and thus, response rates have varied widely. Here, we studied MET alterations in 474 advanced NSCLC patients by nCounter, an RNA-based technique, together with next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and reverse transcriptase polymerase chain reaction (RT-PCR), exploring correlation with clinical benefit. Of the 474 samples analyzed, 422 (89%) yielded valid results by nCounter, which identified 13 patients (3%) with MET Δex14 and 15 patients (3.5%) with very-high MET mRNA expression. These two subgroups were mutually exclusive, displayed distinct phenotypes and did not generally coexist with other drivers. For MET Δex14, 3/8 (37.5%) samples positive by nCounter tested negative by NGS. Regarding patients with very-high MET mRNA, 92% had MET amplification by FISH and/or NGS. However, FISH failed to identify three patients (30%) with very-high MET RNA expression, among which one received MET tyrosine kinase inhibitor treatment deriving clinical benefit. Our results indicate that quantitative mRNA-based techniques can improve the selection of patients for MET-targeted therapies. Amplification Expression Lung cancer MET RNA Skipping Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer